Company intelligence / Profile preview

Receptor BioLogix

Palo Alto or South San Francisco* (*HQ moved during lifetime) , California, United Statespitchbook.com ↗

Ownership: Private
Employees: ~40
Development stage: Phase 2

Overview

The company developed novel protein therapeutics called Intron Fusion Proteins and pan-HER ligand traps targeting the human EGF/HER family for oncology and other indications. Its most advanced asset was the therapeutic vaccine Insegia for GI cancers, which reached Phase III trials before acquisition by Symphogen. The core platform programs were in preclinical development at time of acquisition[5][6].

Therapeutic areas: OncologyMetabolic DisordersImmunology
Modalities: ProteinBiologic
Industry: Biotech

Drug pipeline

2 assets

TORL-1-23

Phase 2

Indications: ovarian cancer

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Receptor BioLogix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Receptor BioLogix.

Explore the full profile